Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2011

Open Access 01-12-2011 | Case report

Anastrozole-related acute hepatitis with autoimmune features: a case report

Authors: Alessandro Inno, Michele Basso, Fabio M Vecchio, Valentina A Marsico, Eleonora Cerchiaro, Ettore D'Argento, Cinzia Bagalà, Carlo Barone

Published in: BMC Gastroenterology | Issue 1/2011

Login to get access

Abstract

Background

Two cases of acute hepatitis occurring during treatment with anastrozole have previously been reported, but the underlying mechanisms of liver injury are still uncertain. We report the case of anastrozole-related acute hepatitis with some autoimmune features.

Case presentation

A 70-year-old woman developed acute hepatitis associated with serum antinuclear antibodies during anastrozole treatment; after drug withdrawal, liver function parameters rapidly improved and serum auto-antibodies were no longer detectable.

Conclusions

Anastrozole-induced hepatotoxicity is a very rare event. Drug-drug interactions or metabolically-mediated damage might be involved, with a possible role of individual susceptibility. Our report suggests that an immune-mediated mechanism may also be considered in anastrozole-related liver injury.
Appendix
Available only for authorised users
Literature
1.
Iwase H: Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast cancer. 2008, 15: 278-290. 10.1007/s12282-008-0071-y.CrossRefPubMed
2.
Janni W, Hepp P: Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev.
3.
Zapata E, Zubiaurre L, Bujanda L, Piérola A: Anastrozole-induced hepatotoxicity. Eur J Gastroenterol Hepatol. 2006, 18: 1233-1234. 10.1097/01.meg.0000243868.64078.af.CrossRefPubMed
4.
de La Cruz L, Romero-Vazquez J, Jiménez-Sáenz M, Padron JR, Herreiras-Gutierrez JM: Severe acute hepatitis in a patient treated with anastrozole. Lancet. 2007, 369: 23-24. 10.1016/S0140-6736(07)60017-8.CrossRefPubMed
5.
Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RNM, Phillips M, Portmann BG, Poulsen H, Scheuer PJ, Schimd M, Thaler H: Histological grading and staging of chronic hepatitis. J Hepatol. 1995, 22: 696-699. 10.1016/0168-8278(95)80226-6.CrossRefPubMed
6.
The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group: Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006, 7: 633-643. 10.1016/S1470-2045(06)70767-7.CrossRef
7.
Danan G, Benichou C: Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993, 46: 1323-1330. 10.1016/0895-4356(93)90101-6.CrossRefPubMed
8.
Grimm SW, Dyroff MC: Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos. 1997, 25: 598-602.PubMed
9.
Horikiri Y, Suzuki T, Mizobe M: Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci. 1998, 87: 289-294. 10.1021/js970316d.CrossRefPubMed
10.
Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T: Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000, 55: 843-852. 10.1007/s002280050706.CrossRefPubMed
11.
Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW, International Autoimmune Hepatitis Group: Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008, 48: 169-176. 10.1002/hep.22322.CrossRefPubMed
12.
Björnsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, Neuhauser M, Lindor K: Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010, 51: 2040-2048.CrossRefPubMed
13.
Laroche M, Borg S, Lassoued S, De Lafontan B, Roché H: Joint pain with aromatase inhibitors: abnormal frequency of Sjogren's syndrome. J Rheumatol. 2007, 34: 2259-2263.PubMed
14.
Conti-Beltraminelli M, Pagani O, Ballerini G, Richetti A, Graffeo R, Ruggeri M, Forni V, Pianca S, Schönholzer C, Mainetti C, Cavalli F, Goldhirsch A: Henoch-Schönlein purpura (HSP) during treatment with anastrozole. Ann Oncol. 2007, 18: 205-207. 10.1093/annonc/mdl350.CrossRefPubMed
15.
Morel B, Marotte H, Miossec P: Will steroidal aromatase inhibitors induce rheumatoid arthritis?. Ann Rheum Dis. 2007, 66: 557-558. 10.1136/ard.2006.066159.CrossRefPubMedPubMedCentral
Metadata
Title
Anastrozole-related acute hepatitis with autoimmune features: a case report
Authors
Alessandro Inno
Michele Basso
Fabio M Vecchio
Valentina A Marsico
Eleonora Cerchiaro
Ettore D'Argento
Cinzia Bagalà
Carlo Barone
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2011
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-11-32

Other articles of this Issue 1/2011

BMC Gastroenterology 1/2011 Go to the issue

Research article

The prone 12 o'clock position reduces ileal intubation time during colonoscopy compared to the left lateral 6 o'clock (standard) position

Research article

Diffuse duodenal nodular lymphoid hyperplasia: a large cohort of patients etiologically related to Helicobacter pyloriinfection

Research article

The addition of a pH-sensitive gel improves microemulsion stability for the targeted removal of colonic ammonia

Research article

Evaluation of gastrointestinal symptoms in different patient groups using the visual analogue scale for irritable bowel syndrome (VAS-IBS)

Research article

Imaging in assessing hepatic and peritoneal metastases of gastric cancer: a systematic review

Research article

Transcript levels of Toll-Like receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative Colitis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits